CEO turned informant: How the FDA built a case against executives promising cheap medications

The Quick Take
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to CNBC Top News.
Related
Markets
Asian stocks diverge on soft Australian employment and Anthropic IPO focus
Markets
Citigroup CEO Fraser warns of more tech outages as firms patch tech
Markets
BCE explores potential Telus deal as Quebecor's C$31B proposal faces scrutiny - report
Markets
Musk accuses Zelenskyy of lying about Starshield restrictions in Ukraine
Elon Musk was asked about Zelenskyy claims over the Starshield network, and he said, "I don't want to blow your mind, but Zelenskyy is not always truthful."
